-2.9%
PFE vs MRNA
+806.0%
-808.9%
-59.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +1.3% | -3.1% | -1.9% |
| 7D | -4.5% | -13.8% | +9.4% | -3.6% |
| 30D | -7.2% | -17.7% | +10.5% | -6.3% |
| 3M | -1.1% | +14.3% | -15.4% | -2.6% |
| 6M | +10.8% | +336.0% | -325.2% | -5.7% |
| YTD | +18.0% | +575.9% | -557.9% | -4.7% |
| 1Y | +18.1% | +724.4% | -706.3% | -6.7% |
| 3Y | +11.8% | +160.8% | -149.0% | -4.9% |
| 5Y | -29.0% | -24.4% | -4.5% | -35.7% |
| All | -2.9% | +806.0% | -808.9% | -28.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling